Therapy with Bortezomib plus Dexamethasone Induces Osteoblast Activation in Responsive Patients with Multiple Myeloma-Reference-Cited by-同舟云学术

Therapy with Bortezomib plus Dexamethasone Induces Osteoblast Activation in Responsive Patients with Multiple Myeloma

Published:2007-08-01 Issue:2 Volume:86 Page:180-185
ISSN:0925-5710
Container-title:International Journal of Hematology
language:
Short-container-title:International Journal of Hematology

Author:

Ozaki Shuji,Tanaka Osamu,Fujii Shiro,Shigekiyo Yuri,Miki Hirokazu,Choraku Masahito,Kagawa Kumiko,Asano Jin,Takeuchi Kyoko,Kitazoe Ken-ichi,Hashimoto Toshihiro,Abe Masahiro,Matsumoto Toshio

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://www.springerlink.com/index/pdf/10.1532/IJH97.07030

Reference34 articles.

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.

2. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis. 2004;32:290-292.

3. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood. 2004;103:20-32.

4. Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006;42:1564-1573.

5. Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004;104:2484-2491.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and clinical outcomes of vitamin D deficiency among Japanese multiple myeloma patients: a single-center observational study;Supportive Care in Cancer;2023-09

2. Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors;International Journal of Hematology;2023-04-11

3. Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents;Journal of Bone and Mineral Metabolism;2023-03-01

4. Drug Targeting and Conventional Treatment of Multiple Myeloma: Analysis of Target-specific Nanotherapies in Disease Models;Current Drug Therapy;2022-10

5. Drug Discovery of DKK1 Inhibitors;Frontiers in Pharmacology;2022-03-09